Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
alemtuzumab + donor hematopoietic stem cells
- Development stage
- Unknown
- Lead developer
- Sanofi
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
This investigational combination regimen, developed by Northwestern University's Comprehensive Transplant Center, is designed to induce immunologic tolerance in HLA-identical sibling kidney transplant recipients. The protocol utilizes alemtuzumab (Campath-1H), a monoclonal antibody targeting the CD52 antigen, as an induction agent to deplete host lymphocytes and monocytes. This is followed by infusions of purified donor CD34+ hematopoietic stem cells (DHSC) to establish cellular chimerism and donor-specific unresponsiveness. The ultimate goal of the regimen is to allow for the complete withdrawal of maintenance immunosuppressive therapy within 24 months post-transplant. Clinical trial results from NCT00619528 have demonstrated durable tolerance in a subset of patients, potentially eliminating the long-term side effects associated with chronic immunosuppression.
- Brand names
- CampathLemtradaMabCampath
- Other names
- DHSC and Campath-1Hdonor CD34+ hematopoietic stem cells + alemtuzumabdonor hematopoietic stem cells + Campath-1H
02
Targets
CD52 (CD52 Antigen)
Beyond the preview
Go deeper on alemtuzumab + donor hematopoietic stem cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on alemtuzumab + donor hematopoietic stem cells.